GW Pharmaceuticals Announces Agreement on Sativex Pricing in Germany


London, UK; 23 September 2013: GW plc (AIM: GWP, Nasdaq: GWPH, “GW”) announced today that for a revised mutually-acceptable reimbursement price for ® has been reached between Almirall S.A., GW’s commercial partner in , and the German National Association of Statutory Health Insurance Funds (GKV-SV). This new agreement has resulted in an increase to the previously reduced price imposed by the German authorities in March 2013 which Almirall had considered to be unacceptable.

“We are pleased to have a positive outcome to discussions that result in an acceptable reimbursement price for Sativex® in Germany, Europe’s largest potential market for Sativex®. This agreement ensures that people suffering from Multiple Sclerosis spasticity in Germany will have long-term access to this important medicine,” stated Justin Gover, GW’s Chief Executive Officer.

It is estimated that approximately 4,000 patients are currently being treated with Sativex® in Germany.

“Almirall is committed to meeting the needs of MS patients and this is the reason we have been determined over recent months to achieve an appropriate resolution of the reimbursement price in Germany,” said Farid Taha, General Manager of Almirall Hermal Company. “Sativex® represents an important advance in the symptomatic treatment of MS spasticity and this new agreement provides doctors and patients in Germany with the necessary assurance that Sativex® represents not only a recognised therapeutic benefit, but will also be available on prescription for the long-term.”

The full text of the joint announcement issued by Almirall and the GKV-SV is below. (NOTE: the following press release is translated into English for the convenience of the reader. Some variation may have occurred in this translation.)

Reimbursement amount for therapeutic agent for MS agreed upon

Berlin, 23 September 2013 – The pharmaceutical company Almirall Hermal…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS